Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Subscribe To Our Newsletter & Stay Updated